A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01569750
Recruitment Status : Completed
First Posted : April 3, 2012
Last Update Posted : August 22, 2017
Pharmacyclics LLC.
Information provided by (Responsible Party):
Janssen Research & Development, LLC